Search

Your search keyword '"Elkis, H"' showing total 180 results
Start Over Author "Elkis, H"

Refine your results

more »

more »

more »

more »
180 results on '"Elkis, H"'

2. Randomized, double-blind, sham-controlled trial to evaluate the efficacy and tolerability of electroconvulsive therapy in patients with clozapine-resistant schizophrenia

Author

Melzer-Ribeiro, D.L., primary, Napolitano, I.C., additional, Leite, S.A., additional, Alencar de Souza, J.A., additional, Vizzotto, A.D.B., additional, Di Sarno, E.S., additional, Fortes, M., additional, Gomes, M.L., additional, de Oliveira, G.M., additional, Avrichir, B.S., additional, Talib, L.L., additional, Correll, C.U., additional, and Elkis, H., additional

Published
2023
Full Text
View/download PDF

3. Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability

Author

Gattaz WF, Saracco-Alvarez R, Daltio CS, Van de Bilt MT, Ortegón JJ, Villaseñor-Bayardo SJ, Louzã M, Elkis H, Soares B, Cabrera Jaramillo P, Lawson F, and Díaz-Galvis L

Subjects
paliperidone palmitate, recent onset, acute phase, schizophrenia, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Wagner F Gattaz,1 Ricardo Saracco-Alvarez,2 Claudiane Salles Daltio,3 Martinus T Van de Bilt,1 Jose Julian Ortegón,4 Sergio J Villaseñor-Bayardo,5 Mario Louzã,6 Helio Elkis,6 Bernardo Soares,7 Patricia Cabrera Jaramillo,7 Fabio Lawson,7 Leonardo Díaz-Galvis8 1Laboratory of Neuroscience (LIM27), Instituto de Psiquiatria do Hospital das Clinicas da Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil; 2Instituto Nacional de Psiquiatría Ramón de la Fuentel, México D.F., México; 3Proesq - Unifesp Schizophrenia Program - Federal University of São Paulo, São Paulo, Brazil; 4Centro de Investigaciones del Sistema Nervioso, Grupo Cisne, Bogotá, Colombia; 5University of Guadalajara, Mexico, Hospital Civil de Guadalajara, “Fray Antonio Alcalde”, Guadalajara, Mexico; 6Instituto de Psiquiatria do HCFMUSP, São Paulo, Brazil; 7Medical Affairs, Janssen, Brazil; 8Medical Affairs, Janssen Canada, Toronto, ON, CanadaCorrespondence: Leonardo Díaz-GalvisDepartment of Medical Affairs, Janssen Inc, 19 Green Belt Dr, Toronto, ON M3C 1L9, CanadaTel +1 416 382 5020Email jldiaz01@its.jnj.comBackground: Paliperidone palmitate is a long-acting, second-generation antipsychotic (SGA) indicated for the treatment of acute exacerbations and maintenance treatment of adults with schizophrenia. This study addressed the response to paliperidone palmitate in Latin American patients with acute symptoms and recently diagnosed schizophrenia.Objective: Explore the efficacy and tolerability of paliperidone palmitate administered once a month for 4 months in patients with acute phase and recent diagnosis (within 1– 6 years) of schizophrenia in 3 Latin American countries.Methods: This was a non-randomized, open-label, multicenter study with paliperidone palmitate injected intramuscularly in the deltoid muscle at an initial loading dose of 150 mg eq. (234 mg) on day 1 and 100 mg eq. (156 mg) on day 8 (± 4 days). The recommended maintenance dose was 75 mg eq. (117 mg) from day 36 to day 92. Efficacy was evaluated with PANSS and CGI-S. The last observation carried forward (LOCF) was used for efficacy analysis for imputation of missing data; no adjustments were made for multiplicity. Adverse events were evaluated during treatment.Results: The patient retention rate was 84.0% (144 patients received study drug; 121 finished the study). The percentage of patients with a reduction of at least 30% in PANSS total score compared to baseline gradually increased during the study, and at the end, 78.4% of patients showed response. The PANSS total score and CGI-S scores decreased significantly from baseline to LOCF endpoint (P < 0.0001 for both); significant reduction in PANSS total score was observed at day 8 and persisted to the end of the study. Most common adverse events were muscle rigidity (11.8%), akathisia (11.1%), injection-site pain (7.6%), weight gain (7.6%), and insomnia (7.6%).Conclusion: Paliperidone palmitate was efficacious in Latin American patients studied with an acute exacerbation and recent diagnosis of schizophrenia, and no new safety signals were identified.Keywords: paliperidone palmitate, recent onset, acute phase, schizophrenia

Published
2020

4. Correlation of Health-Related Quality of Life in Clinically Stable Outpatients with Schizophrenia

Author

Domenech C, Pastore A, Altamura AC, Bernasconi C, Corral R, Elkis H, Evans J, Malla A, Margari F, Krebs MO, Nordstroem AL, Zink M, and Haro JM

Subjects
schizophrenia, health-related quality of life, epidemiology, persistent symptoms, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Cristina Domenech,1,2 Adriana Pastore,3 A Carlo Altamura,4 Corrado Bernasconi,5 Ricardo Corral,6 Helio Elkis,7 Jonathan Evans,8 Ashok Malla,9 Francesco Margari,3 Marie-Odile Krebs,10 Anna-Lena Nordstroem,5 Mathias Zink,11 Josep Maria Haro1,2 1Universitat de Barcelona, Barcelona, Spain; 2Parc Sanitari Sant Joan de Déu, CIBERSAM, Institut de Recerca Sant Joan de Déu, Barcelona, Spain; 3Department of Basic Medical Science, Neuroscience and Sense Organs, ‘Policlinico’ Hospital, University of Bari ‘Aldo Moro’, Bari, Italy; 4University of Milan, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milano, Italy; 5F. Hoffmann-La Roche Ltd, Basel, Switzerland; 6Fundación para el Estudio y Tratamiento de las Enfermedades Mentales (FETEM), Buenos Aires, Argentina; 7Departamento e Instituto de Psiquiatria – FMUSP, Sao Paulo, Brazil; 8Centre for Academic Mental Health, University of Bristol, Bristol, UK; 9Douglas Mental Health University Institute, McGill University, Montréal, QC, Canada; 10Service Hospitalo Universitaire, Laboratoire de Physiopathologie des Maladies Psychiatriques, Inserm, Université Paris Descartes, Hôpital Sainte-Anne, Paris, France; 11Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany and Regional Clinical Centre, Ansbach, GermanyCorrespondence: Josep Maria HaroParc Sanitari Sant Joan de Déu - Antoni Pujadas, 42 - 08830 Sant Boi de Llobregat, Barcelona, SpainTel +34 93 600 26 85Email jmharo@pssjd.orgBackground: Generic health-related quality of life (HRQoL) scales are increasingly being used to assess the effects of new treatments in schizophrenia. The objective of this study is to better understand the usefulness of generic and condition specific HRQoL scales in schizophrenia by analyzing their correlates.Methods: Data formed part of the Pattern study, an international observational study among 1379 outpatients with schizophrenia. Patients were evaluated with the Mini International Neuropsychiatric Inventory, the Clinical Global Impression-Schizophrenia (CGI-SCH) Scale and the Positive and Negative Syndrome Scale (PANSS) and reported their HRQoL using the Schizophrenia Quality of Life Scale (SQLS), the Short Form-36 (SF-36), and the EuroQol-5 Dimension (EQ-5D). The two summary values of the SF-36 (the Mental Component Score and the Physical Component Score, SF-36 MCS and SF-36 PCS) were calculated.Results: Higher PANSS positive dimension ratings were associated with worse HRQoL for the SQLS, EQ-5D VAS, SF-36 MCS, and SF-36 PCS. Higher PANSS negative dimension ratings were associated with worse HRQoL for the EQ-5D VAS, SF-36 MCS, and SF-36 PCS, but not for the SQLS or the EQ-5D tariff. PANSS depression ratings were associated with lower HRQoL in all the scales. There was a high correlation between the HRQoL scales. However, in patients with more severe cognitive/disorganized PANSS symptoms, the SQLS score was relatively higher than the EQ-5D tariff and SF-36 PCS scores.Conclusion: This study has shown substantial agreement between three HRQoL scales, being either generic or condition specific. This supports the use of generic HRQoL measures in schizophrenia.Clinicaltrials.gov identifier: NCT01634542 (July 6, 2012, retrospectively registered).Keywords: schizophrenia, health-related quality of life, epidemiology, persistent symptoms

Published
2019

5. Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia

Author

Louzã M, Elkis H, Ruschel S, de Oliveira IR, Bressan RA, Belmonte-de-Abreu P, Grabowski H, and Appolinário JC

Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Mário Rodrigues Louzã1, Helio Elkis1, Sandra Ruschel2, Irismar Reis de Oliveira3, Rodrigo Affonseca Bressan4, Paulo Belmonte-de-Abreu5, Hamilton Grabowski6, José Carlos Appolinário71Universidade de São Paulo, São Paulo; 2Hospital Mário Kroeff, Rio de Janeiro; 3Universidade Federal da Bahia, Salvador; 4Universidade Federal de São Paulo, São Paulo; 5Universidade Federal do Rio Grande do Sul, Porto Alegre; 6Hospital Bom Retiro, Curitiba; 7Janssen-Cilag Farmaceutica Ltda, São Paulo, BrazilBackground: Long-acting injectable antipsychotics may improve medication adherence, thereby improving overall treatment effectiveness. This study aimed to evaluate the effectiveness, safety, and tolerability of risperidone long-acting injection in schizophrenic patients switched from oral antipsychotic medication.Methods: In a 12-month, multicenter, open-label, noncomparative study, symptomatically stable patients on oral antipsychotic medication with poor treatment adherence during the previous 12 months received intramuscular injections of risperidone long-acting injection (25 mg starting dose) every 2 weeks. The primary endpoint was the change in Positive and Negative Syndrome Scale (PANSS) total score.Results: Of the 60 patients who were screened, 53 received at least one injection (safety population), and 51 provided at least one postbaseline assessment. Mean PANSS total scores improved significantly throughout the study and at endpoint. Significant improvements were also observed in Clinical Global Impression of Severity, Personal and Social Performance, and Drug Attitude Inventory scales. Risperidone long-acting injection was safe and well-tolerated. Severity of movement disorders on the Extrapyramidal Symptom Rating Scale was reduced significantly. The most frequently reported adverse events were insomnia (22.6%), increased prolactin (17.0%), and weight gain (13.2%).Conclusion: Risperidone long-acting injection was associated with significant symptomatic improvements in stable patients with schizophrenia following a switch from previous antipsychotic medications.Keywords: patient compliance, adherence, risperidone, delayed-action preparations, schizophrenia

Published
2011

7. Can the Positive and Negative Syndrome scale (PANSS) differentiate treatment-resistant from non-treatment-resistant schizophrenia? A factor analytic investigation based on data from the Pattern cohort study

Author

Freitas R, Dos Santos B, Altamura C, Bernasconi C, Corral R, Evans J, Malla A, Krebs MO, Nordstroem AL, Zink M, Haro JM, and Elkis H

Abstract

Treatment-Resistant Schizophrenia (TRS) and Non-Treatment-Resistant Schizophrenia (NTRS) may represent different subtypes of schizophrenia. However, few studies have investigated their PANSS symptom dimensions by Exploratory (EFA) or Confirmatory (CFA). Data from the present study are derived from 1429 patients of the Pattern study. TRS was defined by the use of clozapine in the previous year whereas NTRS by the use of non-clozapine antipsychotics ("by proxy"). Factors were chosen based on the Kaiser criterion and considered valid when loadings were greater than or equal to 0.5. The fit to the data was evaluated by CFA in comparison with well-established PANSS models, using fit indexes. The EFA yielded similar five-factor model in both groups: Negative, Positive, Anxiety/Depression, Cognitive and Excited. CFA showed a satisfactory, but not perfect, fit to the data, as compared with the previous PANSS factor analytic models. Despite the limitations regarding the 'by proxy' definition of TRS, the results of the present study show that there are no differences in the factorial structure of PANSS in patients with TRS and NTRS.

Published
2019

8. Health-related quality of life in outpatients with schizophrenia: factors that determine changes over time

Author

CRISTINA DOMENCH ABELLA, Altamura C, Bernasconi C, Corral R, Elkis H, Evans J, Malla A, Krebs MO, Nordstroem AL, Zink M, and Haro JM

Subjects
Course, Schizophrenia, Community, Symptoms, humanities, Health-related quality of life
Abstract

PURPOSE: The objective of this study was to analyze the clinical factors associated with changes in HRQoL in outpatients with schizophrenia using both generic and condition-specific HRQoL scales. METHODS: Adult outpatients with schizophrenia at least 18 years of age who did not have an acute psychotic exacerbation in the 3 months prior to baseline were recruited. PANSS dimensions were calculated based on Lindenmayer et al.'s five factors. HRQoL data were assessed by patients using the Schizophrenia Quality of Life Scale (SQLS), the Short Form-36 (SF-36), and the EuroQol-5 Dimension (EQ-5D) questionnaires. RESULTS: Out of the 1345 patients included at baseline, 1196 (89%) were evaluated at 12 months. Regression models showed that the factor most consistently associated with HRQoL at endpoint was change in the PANSS negative symptoms score. A decrease in the PANSS negative symptoms score from baseline to 1 year was associated with a decrease in HRQoL during the same period. There were also significant associations of the change in PANSS excitatory factor with all the HRQoL scales except the SF-36 PCS. Female gender was associated with a decrease in all HRQoL ratings. There was also a relationship between years since onset and HRQoL. The longer the time since illness onset, the larger the decrease in HRQoL. CONCLUSIONS: This study has found that, in outpatients with schizophrenia, changes in negative and excitement symptoms may have a greater an association with HRQoL than changes in positive, cognitive and depressive symptoms.

Published
2018

9. Understanding the course of persistent symptoms in schizophrenia: Longitudinal findings from the pattern study

Author

Haro JM, Altamura C, Corral R, Elkis H, Evans J, Krebs MO, Zink M, Malla A, Méndez JI, Bernasconi C, Lalonde J, and Nordstroem AL

Subjects
Recovery, Remission, Naturalistic, Relapse, Negative symptoms, Positive symptoms
Abstract

The Pattern study was conducted to provide longitudinal observational data for individual patients with persistent symptoms of schizophrenia. Pattern is an international, multicenter, non-interventional, prospective cohort study of schizophrenia outpatients who were not considered to be in recovery. In the longitudinal phase reported herein, patients were assessed over 1 year using different clinical rating scales. Patient management followed routine local clinical practice. Primary outcome was disease state, defined by the Positive and Negative Syndrome Scale (PANSS), Negative Symptom Factor Score (NSFS), Positive Symptom Factor Score (PSFS), and Personal and Social Performance (PSP) Scale. In total, 1344 protocol-compliant patients (70.9% male) were included. Patients showed a high stability in disease state between consecutive study visits. Persistent negative persistent symptoms and symptomatic remission were the most prevalent and stable disease states. Patients in relapse generally transitioned to negative persistent symptoms or to symptomatic remission. PANSS, PSP, and quality of life ratings remained relatively stable. Relapses occurred in 10% of patients; probability of relapse was associated with younger age, extra-pyramidal symptoms, and more antipsychotic medications. Despite treatment, schizophrenia symptoms tend to remain stable over time, without overall improvement. One of the greatest challenges in schizophrenia is attainment of full symptom remission.

Published
2018

11. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology

Author

Howes, O.D. (Oliver D.), McCutcheon, R. (Rob), Agid, O. (Ofer), De Bartolomeis, A. (Andrea), Beveren, N.J.M. (Nico) van, Birnbaum, M.L. (Michael L.), Bloomfield, M.A.P. (Michael A.P.), Bressan, R.A. (Rodrigo A.), Buchanan, R.W. (Robert W.), Carpenter, W.T. (William T.), Castle, D.J. (David J.), Citrome, L. (Leslie), Daskalakis, Z.J. (Zafiris J.), Davidson, M.W. (Michael ), Drake, R.J. (Richard J.), Dursun, S. (Serdar), Ebdrup, B.H. (Bjørn H.), Elkis, H. (Helio), Falkai, P. (Peter), Fleischacker, W.W. (W. Wolfgang), Gadelha, A. (Ary), Gaughran, F. (Fiona), Glenthøj, B.Y. (Birte Y.), Graff-Guerrero, A. (Ariel), Hallak, J.E.C. (Jaime E.C.), Honer, W.G. (William G.), Kennedy, J.L., Kinon, B.J. (Bruce J.), Lawrie, S. (Stephen), Lee, J. (Jimmy), Leweke, F.M. (F. Markus), MacCabe, J.H. (James), McNabb, C.B. (Carolyn B.), Meltzer, H. (Herbert), Möller, H.-J. (Hans-Jürgen), Nakajima, S. (Shinchiro), Pantelis, C. (Christos), Marques, T.R. (Tiago Reis), Remington, G. (Gary), Rossell, S.L. (Susan L.), Russell, B.R. (Bruce R.), Siu, C.O. (Cynthia O.), Suzuki, T. (Takefumi), Sommer, I.E. (Iris E.), Taylor, D. (David), Thomas, N. (Neil), Üçok, A. (Alp), Umbricht, D. (Daniel), Walters, J.T. (James), Kane, J. (John), Correll, C.U. (Christoph U.), Howes, O.D. (Oliver D.), McCutcheon, R. (Rob), Agid, O. (Ofer), De Bartolomeis, A. (Andrea), Beveren, N.J.M. (Nico) van, Birnbaum, M.L. (Michael L.), Bloomfield, M.A.P. (Michael A.P.), Bressan, R.A. (Rodrigo A.), Buchanan, R.W. (Robert W.), Carpenter, W.T. (William T.), Castle, D.J. (David J.), Citrome, L. (Leslie), Daskalakis, Z.J. (Zafiris J.), Davidson, M.W. (Michael ), Drake, R.J. (Richard J.), Dursun, S. (Serdar), Ebdrup, B.H. (Bjørn H.), Elkis, H. (Helio), Falkai, P. (Peter), Fleischacker, W.W. (W. Wolfgang), Gadelha, A. (Ary), Gaughran, F. (Fiona), Glenthøj, B.Y. (Birte Y.), Graff-Guerrero, A. (Ariel), Hallak, J.E.C. (Jaime E.C.), Honer, W.G. (William G.), Kennedy, J.L., Kinon, B.J. (Bruce J.), Lawrie, S. (Stephen), Lee, J. (Jimmy), Leweke, F.M. (F. Markus), MacCabe, J.H. (James), McNabb, C.B. (Carolyn B.), Meltzer, H. (Herbert), Möller, H.-J. (Hans-Jürgen), Nakajima, S. (Shinchiro), Pantelis, C. (Christos), Marques, T.R. (Tiago Reis), Remington, G. (Gary), Rossell, S.L. (Susan L.), Russell, B.R. (Bruce R.), Siu, C.O. (Cynthia O.), Suzuki, T. (Takefumi), Sommer, I.E. (Iris E.), Taylor, D. (David), Thomas, N. (Neil), Üçok, A. (Alp), Umbricht, D. (Daniel), Walters, J.T. (James), Kane, J. (John), and Correll, C.U. (Christoph U.)

Abstract

Objective: Research and clinical translation in schizophrenia is limited by inconsistent definitions of treatment resistance and response. To address this issue, the authors evaluated current approaches and then developed consensus criteria and guidelines. Method: A systematic review of randomized antipsychotic clinical trials in treatment-resistant schizophrenia was performed, and definitions of treatment resistance were extracted. Subsequently, consensus operationalized criteria were developed through 1) a multiphase, mixed methods approach, 2) identification of key criteria via an online survey, and 3) meetings to achieve consensus. Results: Of 2,808 studies identified, 42 met inclusion criteria. Of these

Published
2017
Full Text
View/download PDF

13. Understanding the impact of persistent symptoms in schizophrenia: Cross-sectional findings from the Pattern study

Author

Haro JM, Altamura C, Corral R, Elkis H, Evans J, Malla A, Krebs MO, Zink M, Bernasconi C, Lalonde J, and Nordstroem AL

Subjects
mental disorders, Epidemiology, Functional impairment, Persistent negative symptoms, Persistent positive symptoms, Quality of life, Schizophrenia
Abstract

The high societal burden of schizophrenia is largely caused by the persistence of symptoms and accompanying functional impairment. To date, no studies have specifically assessed the course of persistent symptoms or the individual contributions of positive and negative symptoms to patient functioning. The cross-sectional analysis of the Pattern study provides an international perspective of the burden of schizophrenia.

Published
2015

14. Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness.

Author

Torres, US, Duran, FLS, Schaufelberger, MS, Crippa, JAS, Louzã, MR, Sallet, PC, Kanegusuku, CYO, Elkis, H, Gattaz, WF, Bassitt, DP, Zuardi, AW, Hallak, JEC, Leite, CC, Castro, CC, Santos, AC, Murray, RM, Busatto, GF, Torres, US, Duran, FLS, Schaufelberger, MS, Crippa, JAS, Louzã, MR, Sallet, PC, Kanegusuku, CYO, Elkis, H, Gattaz, WF, Bassitt, DP, Zuardi, AW, Hallak, JEC, Leite, CC, Castro, CC, Santos, AC, Murray, RM, and Busatto, GF

Abstract

BACKGROUND: Structural brain abnormalities in schizophrenia have been repeatedly demonstrated in magnetic resonance imaging (MRI) studies, but it remains unclear whether these are static or progressive in nature. While longitudinal MRI studies have been traditionally used to assess the issue of progression of brain abnormalities in schizophrenia, information from cross-sectional neuroimaging studies directly comparing first-episode and chronic schizophrenia patients to healthy controls may also be useful to further clarify this issue. With the recent interest in multisite mega-analyses combining structural MRI data from multiple centers aiming at increased statistical power, the present multisite voxel-based morphometry (VBM) study was carried out to examine patterns of brain structural changes according to the different stages of illness and to ascertain which (if any) of such structural abnormalities would be specifically correlated to potential clinical moderators, including cumulative exposure to antipsychotics, age of onset, illness duration and overall illness severity. METHODS: We gathered a large sample of schizophrenia patients (161, being 99 chronic and 62 first-episode) and controls (151) from four previous morphometric MRI studies (1.5 T) carried out in the same geographical region of Brazil. Image processing and analyses were conducted using Statistical Parametric Mapping (SPM8) software with the diffeomorphic anatomical registration through exponentiated Lie algebra (DARTEL) algorithm. Group effects on regional gray matter (GM) volumes were investigated through whole-brain voxel-wise comparisons using General Linear Model Analysis of Co-variance (ANCOVA), always including total GM volume, scan protocol, age and gender as nuisance variables. Finally, correlation analyses were performed between the aforementioned clinical moderators and regional and global brain volumes. RESULTS: First-episode schizophrenia subjects displayed subtle volumetric deficits r

Published
2016

15. Therapy-Resistant Schizophrenia

Author

Elkis, H., Meltzer, H.Y, Elkis, H., and Meltzer, H.Y

Subjects
Antipsychotic drugs, Schizophrenia--Chemotherapy, Drug resistance
Abstract

The psychotic symptoms of up to 30% of schizophrenic patients do not respond adequately to treatment with antipsychotic drugs, other than clozapine. These refractory patients are generally among the most disabled of all people with schizophrenia and require special assessment and treatment. This volume presents the latest research and recommendations on the definition, causes and therapy of treatment-resistant schizophrenia (TRS). Methods for identification and optimal management of TRS are reviewed. Clozapine and other atypical antipsychotic drugs which are the primary treatment for TRS, as well as non-pharmacologic treatments such as transcranial magnetic stimulation, cognitive behavior therapy and ECT are discussed in depth. Potential causative factors and identifying features such as genetic factors, poor premorbid functioning, longer duration of untreated psychosis, and biological measures such as structural and functional brain abnormalities are also reviewed in depth in the present volume.

Published
2010

18. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia : Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.

Author

Hasan, A, Falkai, P, Wobrock, T, Lieberman, J, Glenthöj, B, Gattaz, W F, Thibaut, F, Möller, H-J, Altamura, C, Andreasen, N, Barnes, TRE, Ceylan, ME, Olliver, JC, Crow, T, Danaci, AE, David, A, Davidson, M, Deakin, B, Elkis, H, Farde, L, Gaebel, W, Gallhofer, B, Gerlach, J, Hirsch, SR, Hojaij, CR, Hwang, M, Hwo, HG, Verniaminov Jablensky, A, Jarema, J, Kane, J, Koijima, T, Larach, V, McGorry, P, Meltzer, H, Mosolov, S, Moussaoui, D, Olie, J-P, Palha, AP, Sarandöl, A, Sato, M, Sauer, Heinrich, Schooler, N, Tanell, B, von Knorring, L, Weinberger, D, Yamawaki, S, Hasan, A, Falkai, P, Wobrock, T, Lieberman, J, Glenthöj, B, Gattaz, W F, Thibaut, F, Möller, H-J, Altamura, C, Andreasen, N, Barnes, TRE, Ceylan, ME, Olliver, JC, Crow, T, Danaci, AE, David, A, Davidson, M, Deakin, B, Elkis, H, Farde, L, Gaebel, W, Gallhofer, B, Gerlach, J, Hirsch, SR, Hojaij, CR, Hwang, M, Hwo, HG, Verniaminov Jablensky, A, Jarema, J, Kane, J, Koijima, T, Larach, V, McGorry, P, Meltzer, H, Mosolov, S, Moussaoui, D, Olie, J-P, Palha, AP, Sarandöl, A, Sato, M, Sauer, Heinrich, Schooler, N, Tanell, B, von Knorring, L, Weinberger, D, and Yamawaki, S

Abstract

These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A–F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological treatment of acute schizophrenia and the management of treatment-resistant schizophrenia., De 39 sista författarna ingår i the Wfsbp task force on treatment guidelines for schizophrenia

Published
2012
Full Text
View/download PDF

20. Guidelines for biological Treatment of Schizophrenia, : Part 1: Acute Treatment of Schizophrenia and Part 2: Long-term Treatment of Schizophrenia

Author

Falkai, P, Wobrock, T, Lieberman, J, Glenthoj, B, Gattaz, WF, Möller, H-J, Altamura, AC, Andreasen, N, Barnes, T, Beckmann, H, Ciprian-Olliver, J, Crow, T, David, A, Davidson, M, Deakin, B, Elkis, H, Farde, L, Gaebel, W, Gallhofer, B, Gerlach, J, Richard Hirsch, S, Hojaij, CR, Jablensky, A, Jarema, M, Kane, J, Kojima, T, von Knorring, L, Falkai, P, Wobrock, T, Lieberman, J, Glenthoj, B, Gattaz, WF, Möller, H-J, Altamura, AC, Andreasen, N, Barnes, T, Beckmann, H, Ciprian-Olliver, J, Crow, T, David, A, Davidson, M, Deakin, B, Elkis, H, Farde, L, Gaebel, W, Gallhofer, B, Gerlach, J, Richard Hirsch, S, Hojaij, CR, Jablensky, A, Jarema, M, Kane, J, Kojima, T, and von Knorring, L

Published
2005

36. Components of biological variation in plasma haptoglobin: relationships to plasma fibrinogen and immune variables, including interleukin-6 and its receptor

Author

Maes, M., primary, Cooreman, W., additional, Delanghe, J., additional, Scharpé, S., additional, Wauters, A., additional, Neels, H., additional, D'Hondt, P., additional, Peeters, D., additional, Cosyns, P., additional, Ranjan, R., additional, Bosmans, E., additional, DeMeyer, F., additional, Elkis, H., additional, and Desnyder, R., additional

Published
1995
Full Text
View/download PDF

41. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia part 2: Long-term treatment | Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia parte 2: Tratamento de longo prazo

Author

Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H. -J, Altamura, A. C., Andreasen, N., Barnes, T. R. E., Beckmann, H., Ciprian-Ollivier, J., Crow, T., David, A., Davidson, M., Deakin, B., Elkis, H., Farde, L., Gaebel, W., Gallhofer, B., Gerlach, J., Hirsch, S. R., Hojaij, C. R., Jablensky, A., Kane, J., Kojima, T., Knorring, L., Mcgorry, P., Meltzer, H., Moussaoui, D., Müller-Spahn, F., Olie, J. -P, ANTONIO PALHA, Sato, M., Sauer, H., Schooler, N., Weinberger, D., and Yamawaki, S.

44. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia part 2: Long-term treatment,Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia parte 2: Tratamento de longo prazo

Author

Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H. -J, Altamura, A. C., Nancy Andreasen, Barnes, T. R. E., Beckmann, H., Ciprian-Ollivier, J., Crow, T., David, A., Davidson, M., Deakin, B., Elkis, H., Farde, L., Gaebel, W., Gallhofer, B., Gerlach, J., Hirsch, S. R., Hojaij, C. R., Jablensky, A., Kane, J., Kojima, T., Knorring, L., Mcgorry, P., Meltzer, H., Moussaoui, D., Müller-Spahn, F., Olie, J. -P, Palha, A. P., Sato, M., Sauer, H., Schooler, N., Weinberger, D., and Yamawaki, S.

45. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia part 1: Acute treatment,Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia parte 1: Tratamento agudo

Author

Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H. -J, Altamura, A. C., Nancy Andreasen, Barnes, T. R. E., Beckmann, H., Ciprian-Ollivier, J., Crow, T., David, A., Davidson, M., Deakin, B., Elkis, H., Farde, L., Gaebel, W., Gallhofer, B., Gerlach, J., Hirsch, S. R., Hojaij, C. R., Jablensky, A., Kane, J., Kojima, T., Knorring, L., Mcgorry, P., Meltzer, H., Moussaoui, D., Müller-Spahn, F., Olie, J. -P, Palha, A. P., Sato, M., Sauer, H., Schooler, N., Weinberger, D., and Yamawaki, S.

46. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia part 1: Acute treatment | Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia parte 1: Tratamento agudo

Author

Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H. -J, Altamura, A. C., Andreasen, N., Barnes, T. R. E., Beckmann, H., Ciprian-Ollivier, J., Crow, T., David, A., Davidson, M., Deakin, B., Elkis, H., Farde, L., Gaebel, W., Gallhofer, B., Gerlach, J., Hirsch, S. R., Hojaij, C. R., Jablensky, A., Kane, J., Kojima, T., Knorring, L., Mcgorry, P., Meltzer, H., Moussaoui, D., Müller-Spahn, F., Olie, J. -P, ANTONIO PALHA, Sato, M., Sauer, H., Schooler, N., Weinberger, D., and Yamawaki, S.

50. Response to Markota et al. "Clinical heterogeneity and ECT in patients with clozapine resistant schizophrenia" SCHRES-D-24-00481.

Author

Elkis H, Melzer-Ribeiro DL, and Napolitano IC

Subjects
Humans, Schizophrenia, Treatment-Resistant drug therapy, Schizophrenia drug therapy, Clozapine pharmacology, Clozapine therapeutic use, Electroconvulsive Therapy, Antipsychotic Agents pharmacology
Abstract

Competing Interests: Declaration of competing interest Helio Elkis received a research grant from FAPESP and honoraria for participation as a member of advisory boards, speaker, or travel support from the following pharmaceutical companies: Aché, Cristália, Daiichi- Sankyo, Janssen, Mantecorp- Hypera, Teva and Boehringer- Ingelheim. Debora Luciana Melzer-Ribeiro and Isabel Cristina Napolitano have no conflict of interests.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results